Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Goals
Fat LossMuscle BuildingInjury HealingAnti-AgingCognitive EnhancementSleep OptimizationImmune SupportGut HealingSkin RejuvenationSexual Health
Peptides
Adipotide
Weight Management
AOD-9604
Weight Management
BPC-157
Healing & Recovery
Cagrilintide
Weight Management
CJC-1295
Growth Hormone
DSIP
Sleep & Recovery
Epithalon
Anti-Aging
GHK-Cu
Anti-Aging
GHRP-2
Growth Hormone
HCG
Hormone Support
Hexarelin
Growth Hormone
HGH
Growth Hormone
IGF-1 LR3
Growth Hormone
Kisspeptin
Hormone Support
Melanotan-2
Cosmetic
MOTS-C
Metabolic
NAD+
Anti-Aging
Oxytocin Acetate
Hormone Support
PEG-MGF
Recovery
PNC-27
Cancer Research
PT-141
Sexual Health
Retatrutide
Weight Management
Selank
Cognitive
Semaglutide
Weight Management
Semax
Cognitive
Sermorelin
Growth Hormone
Snap-8
Cosmetic
SS-31
Mitochondrial
TB-500
Healing & Recovery
Tesamorelin
Growth Hormone
Thymosin Alpha-1
Immune
Tirzepatide
Weight Management
Total Peptides: 32
Back to Home

Peptide Comparison

VIP (Vasoactive Intestinal Peptide)vsTB-500

Endogenous neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties

A powerful fragment of thymosin beta-4 that acts like your body's repair signal—speeding up healing of muscles, tendons, and tissues by promoting cell migration and new blood vessel growth right where you need it most.

Healing & RecoveryHealing & Recovery

At a Glance

Quick
comparison

Dose Range

VIP (Vasoactive Intestinal Peptide)

67 mcg/day–300 mcg/day mcg

TB-500

2–5 mg

Frequency

VIP (Vasoactive Intestinal Peptide)

Once daily

TB-500

Twice weekly

Administration

VIP (Vasoactive Intestinal Peptide)

Intravenous infusion

TB-500

Subcutaneous injection

Cycle Length

VIP (Vasoactive Intestinal Peptide)

Ongoing/indefinite

TB-500

4-6 weeks

Onset Speed

VIP (Vasoactive Intestinal Peptide)

Moderate (1-2 weeks)

TB-500

Moderate (1-2 weeks)

Evidence Level

VIP (Vasoactive Intestinal Peptide)

Moderate human trials (Phase 1-2)

TB-500

Moderate human trials (Phase 1-2)

Efficacy

Benefit
ratings

VIP (Vasoactive Intestinal Peptide)
TB-500

Cardiovascular

VIP (Vasoactive Intestinal Peptide)88%
TB-5000%

Anti-Inflammatory

VIP (Vasoactive Intestinal Peptide)85%
TB-5000%

Neuroprotection

VIP (Vasoactive Intestinal Peptide)78%
TB-5000%

Healing Speed

VIP (Vasoactive Intestinal Peptide)0%
TB-50095%

Tissue Repair

VIP (Vasoactive Intestinal Peptide)0%
TB-50093%

Anti-Scarring

VIP (Vasoactive Intestinal Peptide)0%
TB-50088%

Technical Data

Compound
specifications

VIP (Vasoactive Intestinal Peptide)

Molecular Formula

C147H237N43O43S

Molecular Weight

3325.83 Da

Half-Life

Approximately 1-2 minutes in plasma (rapid enzymatic degradation)

Bioavailability

IV: 100%; Inhaled: local pulmonary delivery; short systemic half-life

CAS Number

37221-79-7

TB-500

Molecular Formula

C38H68N10O14

Molecular Weight

889.01 g/mol

Half-Life

2-3 days (systemic)

Bioavailability

High via subcutaneous injection (~100%)

CAS Number

885340-08-9

Protocols

Dosing
tiers

VIP (Vasoactive Intestinal Peptide)

TB-500

starting

2-2.5 mg

Twice weekly

4-6 weeks

Start here to assess your tolerance and response. Many people see good results at this dose. Split your weekly dose into two injections spaced 3-4 days apart (like Monday and Thursday).

standard

4-5 mg

Twice weekly (split into 2-2.5 mg doses)

4-6 weeks

The most commonly used protocol for moderate injuries. Your total weekly dose is 4-5 mg, split into two injections. This is the sweet spot where most users see significant healing benefits.

advanced

5-10 mg

Twice weekly (2.5-5 mg per injection)

4-8 weeks

Higher doses for severe or stubborn injuries. Some protocols use a loading phase of higher doses for 1-2 weeks, then drop to maintenance. Work with a provider for doses above 5 mg weekly.

Applications

Best
suited for

VIP (Vasoactive Intestinal Peptide)

Pulmonary arterial hypertension research

VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on pulmonary arterial hypertension research. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

ARDS and respiratory failure investigation

VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on ards and respiratory failure investigation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-inflammatory therapy development

VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on anti-inflammatory therapy development. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Neuroprotection studies

VIP (Vasoactive Intestinal Peptide) is particularly well-suited for individuals focused on neuroprotection studies. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

TB-500

Athletes Recovering from Muscle Injuries

If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal.

Tendon and Ligament Problems

Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues.

Post-Surgical Recovery

After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline.

Chronic Inflammation and Slow Healers

Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most.

Safety Profile

Side
effects

VIP (Vasoactive Intestinal Peptide)

Common

  • Facial Flushing
  • Diarrhea
  • Nausea

Uncommon

  • Hypotension
  • Tachycardia
  • Cardiovascular Effects

Serious

  • Hypotension
  • Severe Flushing and Facial Erythema

TB-500

Common

  • Injection site redness
  • Mild fatigue or lethargy
  • Mild headache
  • Slight flushing

Uncommon

  • Head rush or lightheadedness
  • Temporary nausea

Serious

  • Allergic reaction

Research Status

Safety
& evidence

VIP (Vasoactive Intestinal Peptide)

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

VIP (Vasoactive Intestinal Peptide) is a 28-amino acid endogenous neuropeptide with moderate evidence from Phase 1-2 human clinical trials. The synthetic pharmaceutical form (aviptadil/RLF-100) received FDA fast-track designation for COVID-19-associated ARDS, indicating recognition of its therapeutic potential. Critical safety considerations: VIP is a potent vasodilator that causes dose-dependent hypotension and compensatory tachycardia—hemodynamic monitoring is essential during IV administration. Common side effects include facial flushing and diarrhea from its GI effects. Phase 2b/3 COVID-19 ARDS trials (196 patients) reported NO serious drug-related adverse events, a favorable safety signal. However, individual responses to vasodilation vary significantly based on baseline cardiovascular status, medications, and underlying conditions. The peptide's short plasma half-life (1-2 minutes) limits systemic accumulation. Inhaled VIP shows excellent local tolerability for pulmonary applications with minimal systemic absorption.

Contraindications

  • xUncontrolled hypotension or hemodynamic instability
  • xSevere cardiac decompensation
  • xNot approved for clinical use outside of trials
  • xInsufficient data for pregnancy and lactation safety

TB-500

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans.

Contraindications

  • xPregnancy or planning to become pregnant
  • xCurrently breastfeeding
  • xActive cancer or history of cancer
  • xKnown allergy to peptide components
  • xChildren and adolescents

Decision Guide

Which is
right for you?

Choose VIP (Vasoactive Intestinal Peptide) if...

  • Pulmonary arterial hypertension research
  • ARDS and respiratory failure investigation
  • Anti-inflammatory therapy development
  • Neuroprotection studies

Choose TB-500 if...

  • Accelerating injury recovery
  • Tendon and ligament healing
  • Reducing chronic inflammation
  • Post-surgical recovery support